MedTrace Logo

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

NCT00112658 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2021-03-08

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective as first-line therapy in treating pancreatic cancer.

PURPOSE: This randomized phase II/III trial is studying how well combination chemotherapy works as first-line therapy in treating patients with metastatic pancreatic cancer.

Conditions

Interventions

DRUG

fluorouracil

DRUG

gemcitabine hydrochloride

DRUG

irinotecan hydrochloride

DRUG

leucovorin calcium

DRUG

oxaliplatin

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Thierry Conroy, MD · Centre Alexis Vautrin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00112658 on ClinicalTrials.gov